Logo

Immatics N.V.

IMTX

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics… read more

Healthcare

Biotechnology

4 years

USD

Exclusive to Premium users

Price

per share adjusted in USD

$8.76

Price

+2.82%

$0.24

Market Cap

$1.065b

Small

Price/Earnings

-

Premium

3y Avg

Premium

5y Avg

Financials Overview

Key metrics over the past few years

-

EBITDA Margin

-

Net Profit Margin

-

Free Cash Flow Margin
Revenue

$130.130m

-

1y CAGR

-

3y CAGR

-

5y CAGR
Earnings

-$73.910m

-

1y CAGR

-

3y CAGR

-

5y CAGR
EPS

-$0.56

-

1y CAGR

-

3y CAGR

-

5y CAGR
Book Value

$464.574m

$567.302m

Assets

$102.728m

Liabilities

$17.116m

Debt
Debt to Assets

3.0%

-0.3x

Debt to EBITDA
Free Cash Flow

-$174.694m

-

1y CAGR

-

3y CAGR

-

5y CAGR

Financial Reports

Earnings and other important metrics. Amounts in EUR.
No items found.
Press Releases
Statements and updates from the company
↑ TopSummaryPriceFinancialsPress Releases